Comparison of the safety of remazolam and propofol for painless gastroenteroscopy in elderly pa-tients:a meta-analysis
Objective To compare the safety of remimazolam and propofol in elderly patients un-dergoing painless gastroenteroscopy.Methods PubMed,Cochrane Library,Embase database,China Knowledge Network,Wanfang Data Knowledge Service Platform,China Biomedical Literature Service System(SinoMed),and VIP Chinese Journal Full Text Database were searched from the creation of the da-tabase to November 2022,and elderly patients undergoing painless gastroenteroscopy were included into the experimental group of remazolam and the control group using propofol in a randomized controlled trial.The literature was carefully reviewed to identify data that met the inclusion and exclusion criteria.The extracted data were analyzed using Review Manager 5.4 statistical software.Results Fifteen trials with a total of 1808 patients were included.The Meta analysis showed that the incidence of injection pain(OR=0.02,95％CI 0.01 to 0.05,P＜0.001),respiratory depression(OR=0.38,95％CI 0.23 to 0.62,P＜0.001),hypoxemia(OR=0.33,95％CI 0.16 to 0.67,P=0.002),bradycardia(OR=0.21,95％CI 0.10 to 0.45,P＜0.001),hypotension(OR=0.22,95％CI 0.16 to 0.30,P＜0.001),awaken time(MD=-1.34 seconds,95％CI-2.35 to-0.34 seconds,P=0.009),and discharge time(MD=-6.67 seconds,95％CI-10.86 to-2.48 seconds,P=0.002)were significantly reduced.Conclusion Compared with propofol,remazolam is more haemodynamically stable when using painless gastroenteroscopy in elderly patients,with a significantly lower incidence of adverse events such as injection pain and respira-tory depression,and a significantly shorter time to wake up and time out of the room,but there are no signif-icant differences in induction time and incidence of dizziness,nausea and vomiting.
万方数据
维普
